An unusual response to 5-azacitidine by a patient with chronic myelomonocytic leukemia.
5‐azacitidine (AZA)
MDS/MPN
chronic myelomonocytic leukemia (CMML)
decitabine (DEC)
hypomethylating agents (HMAs)
myelodysplastic syndromes (MDS)
myeloproliferative neoplasms (MPN)
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
07
06
2023
revised:
10
07
2023
accepted:
19
07
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Hypomethylating agents may be useful in some but not all cases of myelodysplastic syndromes. In some versions of these conditions, this treatment may yield deleterious results. Chronic myelomonocytic leukemia (CMML) is considered to be a heterogeneous group of hematopoietic neoplasms. Usually it shares the features of myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) and is known as MDS/MPN. It occurs mostly in the elderly and has an inherent tendency to transform to acute myeloid leukemia. FDA has approved hypomethylating agents (HMAs) such as 5-azacitidine (AZA) and decitabine (DEC) for the treatment of this disorder. The extent of response rate to AZA varies considerably among patients. Our report describes a patient with CMML who not only did not respond to a conventional dose of intravenous (IV) therapy with AZA, but showed marked progression of the disease with the leucocyte count rising exponentially while undergoing the aforesaid treatment. We believe this is the first such case reported in the currently extant literature.
Identifiants
pubmed: 37546162
doi: 10.1002/ccr3.7748
pii: CCR37748
pmc: PMC10397479
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e7748Informations de copyright
© 2023 The Author. Clinical Case Reports published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
None declared.
Références
Clin Case Rep. 2015 Jul;3(7):551-2
pubmed: 26273440
Br J Haematol. 2014 May;165(3):273-86
pubmed: 24467717
Cancer Biol Med. 2016 Sep;13(3):360-372
pubmed: 27807503
Am J Hematol. 2018 Jun;93(6):824-840
pubmed: 29878489
Am J Hematol. 2021 Mar 1;96(3):379-394
pubmed: 33428785
Front Oncol. 2021 Dec 13;11:801524
pubmed: 34966690
Blood. 2016 Sep 8;128(10):1408-17
pubmed: 27385790
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Blood. 2017 Jul 13;130(2):126-136
pubmed: 28572287
Int J Hematol. 2022 Dec;116(6):961-965
pubmed: 35852697
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Hematol Rep. 2020 Dec 02;12(3):8537
pubmed: 33324479